RSS Feed

Related Articles

Related Categories

UK funds remain on the agenda for Barclays Stockbokers investors

19th November 2012 Print

UK focused funds continued to increase in popularity for investors in October, according to the latest analysis from Barclays Stockbrokers.

The top 20 fund purchases made by Barclays Stockbrokers clients in October revealed strong interest in the UK for a second consecutive month, with seven of the top twenty funds having a UK focus. The AXA Framlington Biotech fund was the top choice in October, having reached second spot in September and only appearing in the top twenty for the first time in July 2012. Global Emerging Markets funds also moved back up the rankings, with Aberdeen Emerging Markets and First State Global Emerging Markets Leaders appearing in second and third spots respectively.

In October 2012 there was a significant increase in fund investments compared to the previous year; October 2012 saw a 202% increase in the value of investments compared to October 2011. The month also saw an 86% increase in funds deals compared to October 2011.

Alastair Thaw, Head of Investor Product at Barclays Stockbrokers, said: "October was a steady month for fund investments, with client appetite for UK focused funds continuing to grow.  However, Emerging Markets funds also regained strength within the top twenty. In October we saw a marked increase (202%) in fund investments compared to the same month in the previous year as investors take action to seek out the best returns available.

"This year we have combined our experience and expertise in stock broking with an expanded and improved fund offering in a single place, meaning our clients have a choice of a wide range of funds which they can access with ease and at competitive prices. With the launch of our regular investment service, investors can choose to add lump sums or drip feed sums into the market over time to build up their investments and maximise tax efficient benefits too."